TrialThe Journal of infectious diseases2022

Three Dose Levels of a Maternal Respiratory Syncytial Virus Vaccine Candidate Are Well Tolerated and Immunogenic in a Randomized Trial in Nonpregnant Women.

Tino F Schwarz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.